Genentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy

Ryan Cross

Senior Science Correspondent

An experimental Alzheimer’s drug and its designer are getting a second chance.
On Tuesday, Sangamo announced it had partnered with Genentech to develop an epigenetic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

GSK sues Moderna over mRNA vaccine patents, seeks 'reasonable royalty'

J&J trims pipeline, including two mid-stage neuroscience studies

J&J’s medtech slump continues, improvements not expected until 2025

Pfizer partners with molecular glue startup Triana in $49M upfront deal

Jazz reports Phase 3 success for Zepzelca in first-line maintenance for small cell lung cancer

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Genen­tech part­ners with cash-strapped Sang­amo on epi­ge­net­ic Alzheimer’s ther­a­py

Senior Science Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Genentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy